Male, mobile, and moneyed: loss to follow-up vs. transfer of care in an urban African antiretroviral treatment clinic

Kara G Marson, Kenneth Tapia, Pamela Kohler, Christine J McGrath, Grace C John-Stewart, Barbra A Richardson, Julia W Njoroge, James N Kiarie, Samah R Sakr, Michael H Chung, Kara G Marson, Kenneth Tapia, Pamela Kohler, Christine J McGrath, Grace C John-Stewart, Barbra A Richardson, Julia W Njoroge, James N Kiarie, Samah R Sakr, Michael H Chung

Abstract

Objectives: The purpose of this study was to analyze characteristics, reasons for transferring, and reasons for discontinuing care among patients defined as lost to follow-up (LTFU) from an antiretroviral therapy (ART) clinic in Nairobi, Kenya.

Design: The study used a prospective cohort of patients who participated in a randomized, controlled ART adherence trial between 2006 and 2008.

Methods: Participants were followed from pre-ART clinic enrollment to 18 months after ART initiation, and were defined as LTFU if they failed to return to clinic 4 weeks after their last scheduled visit. Reasons for loss were captured through phone call or home visit. Characteristics of LTFU who transferred care and LTFU who did not transfer were compared to those who remained in clinic using log-binomial regression to estimate risk ratios.

Results: Of 393 enrolled participants, total attrition was 83 (21%), of whom 75 (90%) were successfully traced. Thirty-seven (49%) were alive at tracing and 22 (59%) of these reported having transferred their antiretroviral care. In the final model, transfers were more likely to have salaried employment [Risk Ratio (RR), 2.7; 95% confidence interval (CI), 1.2-6.1; p=0.020)] and pay a higher monthly rent (RR, 5.8; 95% CI, 1.3-25.0; p=0.018) compared to those retained in clinic. LTFU who did not transfer care were three times as likely to be men (RR, 3.1; 95% CI, 1.1-8.1; p=0.028) and nearly 4 times as likely to have a primary education or less (RR, 3.8; 95% CI, 1.3-10.6; p=0.013). Overall, the most common reason for LTFU was moving residence, predominantly due to job loss or change in employment.

Conclusion: A broad definition of LTFU may include those who have transferred their antiretroviral care and thereby overestimate negative effects on ART continuation. Interventions targeting men and considering mobility due to employment may improve retention in urban African ART clinics.

Clinical trials: The study's ClinicalTrials.gov identifier is NCT00273780.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile of ART eligible…
Figure 1. Trial profile of ART eligible patients screened at Coptic Hope Center.
Figure 2. Attrition outcomes and reasons for…
Figure 2. Attrition outcomes and reasons for loss.

References

    1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. doi:10.1056/NEJM199803263381301. PubMed: .
    1. Abbas UL, Anderson RM, Mellors JW (2006) Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 41: 632-641. . PubMed: .
    1. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL et al. (2002) Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 30: 105-110. doi:10.1097/00126334-200205010-00014. PubMed: .
    1. Brennan AT, Maskew M, Sanne I, Fox MP (2010) The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J International AIDS Society 13: 49.
    1. Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189. doi:10.1097/01.aids.0000226959.87471.01. PubMed: .
    1. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A (2008) Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 22: 1305-1312. doi:10.1097/QAD.0b013e3282fa75b9. PubMed: .
    1. Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB et al. (2007) Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 44: 30-37. doi:10.1097/01.qai.0000248351.10383.b7. PubMed: .
    1. Kaslow RA, Dorak T, Tang JJ (2005) Influence of host genetic variation on susceptibility to HIV type 1 infection. J Infect Dis 191 Suppl 1: S68-S77. doi:10.1086/425269. PubMed: .
    1. Brinkhof MW (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567. doi:10.2471/BLT.07.044248. PubMed: .
    1. Myer L, el-Sadr W (2004) Expanding access to antiretroviral therapy through the public sector--the challenge of retaining patients in long-term primary care. S Afr Med J 94: 273-274. PubMed: .
    1. Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLOS Med 4: e298. doi:10.1371/journal.pmed.0040298. PubMed: .
    1. Fox MP, Rosen S (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 15 Suppl 1: 1-15
    1. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN et al. (2011) A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLOS Med 8: e1000422.
    1. Program NASC (2011) Guidelines for antiretroviral therapy in Kenya.
    1. Fortson JG (2008) The gradient in sub-Saharan Africa: socioeconomic status and HIV/AIDS. Demography 45: 303-322. doi:10.1353/dem.0.0006. PubMed: .
    1. Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC et al. (2010) High rate of loss to clinical follow up among African HIV-infected patients attending a London Clinic: a retrospective analysis of a clinical cohort. J International AIDS Society 13: 29 PubMed: .
    1. Mulissa Z, Jerene D, Lindtjørn B (2010) Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLOS ONE 5: e13268. doi:10.1371/journal.pone.0013268. PubMed: .
    1. Rosen S, Ketlhapile M (2010) Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa. Trop Med Int Health 15 Suppl 1: 98-104. doi:10.1111/j.1365-3156.2010.02512.x. PubMed: .
    1. Tweya H, Gareta D, Chagwera F, Ben-Smith A, Mwenyemasi J et al. (2010) Early active follow-up of patients on antiretroviral therapy (ART) who are lost to follow-up: the 'Back-to-Care' project in Lilongwe, Malawi. Trop Med Int Health 15 Suppl 1: 82-89. doi:10.1111/j.1365-3156.2010.02509.x. PubMed: .
    1. Yu JK (2007) True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 85: 550-554. doi:10.2471/BLT.06.037739. PubMed: .
    1. Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M et al. (2011) Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis 11: 31. doi:10.1186/1471-2334-11-31. PubMed: .
    1. Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S (2010) Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 15 Suppl 1: 48-54. doi:10.1111/j.1365-3156.2010.02514.x. PubMed: .
    1. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr 53: 405-411. doi:10.1097/QAI.0b013e3181b843f0. PubMed: .
    1. Chung MH, Kohler P, Attwa M, Thiga J, John-Stewart GC (2010) Comparing clinic retention between residents and nonresidents of Kibera, Kenya. J Acquir Immune Defic Syndr 53: 422-424. doi:10.1097/QAI.0b013e3181b32bd6. PubMed: .
    1. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E et al. (2010) Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLOS ONE 5: e10584. doi:10.1371/journal.pone.0010584. PubMed: .
    1. Ekouevi DK, Balestre E, Ba-Gomis FO, Eholie SP, Maiga M et al. (2010) Low retention of HIV-infected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health 15 Suppl 1: 34-42. doi:10.1111/j.1365-3156.2010.02505.x. PubMed: .
    1. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C et al. (2011) Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLOS ONE 6: e18453. doi:10.1371/journal.pone.0018453. PubMed: .
    1. Ahonkhai AA, Noubary F, Munro A, Stark R, Wilke M et al. (2012) Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLOS ONE 7: e32993. doi:10.1371/journal.pone.0032993. PubMed: .
    1. Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM et al. (2009) Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic) 8: 139-147. doi:10.1177/1545109709332470.
    1. Mosoko JJ, Akam W, Weidle PJ, Brooks JT, Aweh AJ et al. (2011) Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon. J International AIDS Society 14: 32.
    1. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C et al. (2011) Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr 56: e1-e8. doi:10.1097/QAI.0b013e3181f638ed. PubMed: .
    1. Weigel R, Estill J, Egger M, Harries AD, Makombe S et al. (2012) Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS 26: 365-373. doi:10.1097/QAD.0b013e32834ed814. PubMed: .
    1. Gadkari AS, McHorney CA (2012) Unintentional non-adherence to chronic prescription medications: How unintentional is it really? BMC Health Serv Res 12: 98. doi:10.1186/1472-6963-12-98. PubMed: .
    1. Scuteri A, Najjar SS, Orru’ M, Albai G, Strait J et al. (2009) Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the Sardinia Study. Nutr Metab Cardiovasc Dis 19: 532-541. doi:10.1016/j.numecd.2008.11.004. PubMed: .
    1. Pyne-Mercier LD, John-Stewart GC, Richardson BA, Kagondu NL, Thiga J et al. (2011) The consequences of post-election violence on antiretroviral HIV therapy in Kenya. AIDS Care 23: 562-568. doi:10.1080/09540121.2010.525615. PubMed: .
    1. Bigsten A (1996) The circular migration of smallholders in Kenya. J Afr Econ 5: 1-20. doi:10.1093/oxfordjournals.jae.a020893. PubMed: .
    1. Ogutu ZA (1993) Responding to population pressure in the rural Kenya. GeoJournal 30: 409-419. PubMed: .
    1. Linard C, Gilbert M, Snow RW, Noor AM, Tatem AJ (2012) Population distribution, settlement patterns and accessibility across Africa in 2010. PLOS ONE 7: e31743. doi:10.1371/journal.pone.0031743. PubMed: .
    1. Todaro MP (1996) Income expectations, rural-urban migration and employment in Africa. Int Labour Rev 135: 421-444. PubMed: .
    1. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B et al. (2009) Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 51: 135-139. doi:10.1097/QAI.0b013e3181a44ef2. PubMed: .
    1. Tayler-Smith K, Zachariah R, Manzi M, Kizito W, Vandenbulcke A et al. (2011) Demographic characteristics and opportunistic diseases associated with attrition during preparation for antiretroviral therapy in primary health centres in Kibera, Kenya. Trop Med Int Health 16: 579-584. doi:10.1111/j.1365-3156.2011.02740.x. PubMed: .
    1. Balcha TT, Jeppsson A, Bekele A (2011) Barriers to antiretroviral treatment in Ethiopia: a qualitative study. J Int Assoc Physicians AIDS Care (Chic) 10: 119-125. doi:10.1177/1545109710387674. PubMed: .
    1. Roura M, Busza J, Wringe A, Mbata D, Urassa M et al. (2009) Barriers to sustaining antiretroviral treatment in Kisesa, Tanzania: a follow-up study to understand attrition from the antiretroviral program. AIDS Patient Care STDs 23: 203-210. doi:10.1089/apc.2008.0129. PubMed: .
    1. Dahab M, Kielmann K, Charalambous S, Karstaedt AS, Hamilton R et al. (2011) Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. AIDS Patient Care STDs 25: 53-59. doi:10.1089/apc.2010.0140. PubMed: .
    1. McGuire M, Munyenyembe T, Szumilin E, Heinzelmann A, Le Paih M et al. (2010) Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health 15 Suppl 1: 55-62. doi:10.1111/j.1365-3156.2010.02562.x. PubMed: .
    1. Brinkhof MW, Pujades-Rodriguez M, Egger M (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLOS ONE 4: e5790. doi:10.1371/journal.pone.0005790. PubMed: .

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere